SC 13D

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934*

Resolute Energy Corporation

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

76116A306

(CUSIP Number of Class of Securities)

Michael Kelly, Esq.

Monarch Alternative Capital LP

535 Madison Avenue

New York, NY 10022

Telephone: (212) 554-1700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

Copies to:

Mark Cognetti, Esq.

Michael Brandt, Esq.

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, NY 10019-6099

(212) 728-8000

January 24, 2018

(Date of Event which Requires Filing of this Schedule)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:  ☐

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

  CUSIP No. 76116A306     Page 2 of 8 Pages  

1	NAME OF REPORTING PERSON Monarch Alternative Capital LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS N/A
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 2,073,400
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 2,073,400

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 2,073,400
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.21%
14	TYPE OF REPORTING PERSON PN, IA

SCHEDULE 13D

  CUSIP No. 76116A306     Page 3 of 8 Pages  

1	NAME OF REPORTING PERSON MDRA GP LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS N/A
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 2,073,400
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 2,073,400

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 2,073,400
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.21%
14	TYPE OF REPORTING PERSON PN, HC

SCHEDULE 13D

  CUSIP No. 76116A306     Page 4 of 8 Pages  

1	NAME OF REPORTING PERSON Monarch GP LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS N/A
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 2,073,400
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 2,073,400

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 2,073,400
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.21%
14	TYPE OF REPORTING PERSON OO, HC

Item 1. Security and Issuer

This Schedule 13D relates to common shares, par value $0.0001 per share (“Common Stock”), of Resolute Energy Corporation (the “Issuer”), having its principal executive offices at 1700 Lincoln Street, Suite 2800, Denver, Colorado, 80203.

Item 2. Identity and Background.

(a)    This Schedule 13D is filed jointly by:

(i) Monarch Alternative Capital LP (“MAC”), which serves as advisor to a variety of funds (such funds collectively, the “Funds”) with respect to shares of Common Stock of the Issuer directly owned by the Funds;

(ii) MDRA GP LP (“MDRA GP”), which is the general partner of MAC, with respect to shares of Common Stock indirectly beneficially owned by virtue of such position; and

(iii) Monarch GP LLC (“Monarch GP”), which is the general partner of MDRA GP, with respect to shares of Common Stock indirectly beneficially owned by virtue of such position.

MAC, MDRA GP and Monarch GP are sometimes collectively referred to herein as the “Reporting Persons.”

Set forth on Schedule I hereto is the (i) name, (ii) business address, (iii) present principal occupation or employment, and (iv) citizenship of all of the directors and executive officers or persons holding equivalent positions of Monarch GP (the “Scheduled Persons”, each a “Scheduled Person”).

(b)    The address of MAC, MDRA GP and Monarch GP is 535 Madison Avenue, New York, New York 10022. Schedule I hereto sets forth the principal business address of each Scheduled Person.

(c)    The principal business of MAC is to serve as investment advisor to, and to control the investment activities of, the Funds. The principal business of MDRA GP is to serve as general partner of MAC. The principal business of Monarch GP is to serve as general partner of MDRA GP. Schedule I hereto sets forth the principal occupation or employment of each Scheduled Person.

(d)    None of the Reporting Persons, nor, to the best of their knowledge, any Scheduled Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)     None of the Reporting Persons, nor, to the best of their knowledge, any Scheduled Person has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)     Schedule I hereto sets forth the citizenship of each Scheduled Person.

Item 3. Source and Amount of Funds or Other Consideration

The 2,073,400 shares of Common Stock beneficially owned by the Reporting Persons were acquired in open market transactions. The Funds expended an aggregate of approximately $52,604,536.56 of their own investment capital to acquire the shares held by them.

Item 4. Purpose of Transaction

The Reporting Persons originally acquired shares of Common Stock of the Issuer for investment purposes.

On January 24, 2018, representatives of MAC sent to the Issuer’s chief executive officer and the Issuer’s board of directors (the “Board”) a letter (the “January Letter”).

MAC has proposed in the January Letter that (x) the Issuer increase stockholder representation on the Board by appointing two individuals designated by MAC to the Board as independent directors, (y) the Board form a committee consisting of the two Board members designated by MAC and one other independent Board member for the purpose of exploring potential strategic transactions, and (z) the Issuer engage a reputable financial advisor with deep industry expertise and relationships to assist the newly formed committee and Board in evaluating and executing potential strategic transactions. The summary contained herein of the January Letter is not intended to be complete and is qualified in its entirety by reference to the full text of the January Letter, a copy of which is filed as Exhibit 99.1 hereto and which is incorporated herein by reference.

To date, no understanding has been reached between the Reporting Persons and the Issuer with respect to these issues.

Except as set forth herein, including in any Exhibits hereto, the Reporting Persons have no present plans or proposals that relate to or would result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including the Issuer’s financial position and strategic direction, actions taken by the Board of the Issuer, price levels of the Common Stock, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, purchasing additional Common Stock, other securities or derivative instruments related thereto or selling some or all of their Common Stock, other securities or derivative instruments, engaging in hedging or similar transactions with respect to the Common Stock, and, alone or with others, may engage in communications with other stockholders of the Issuer, knowledgeable industry or market observers, members of the Board, management of the Issuer or other representatives of the Issuer, or other persons, regarding the Issuer, including but not limited to its operations, strategy, management, capital structure and their investment in the Issuer and strategic alternatives that may be available to the Issuer. Such discussions may concern ideas or proposals that, if effected, may result in one or more of the events described in Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a)    Each of MAC, MDRA GP and Monarch GP indirectly beneficially own 2,073,400 shares of Common Stock. Such shares represent 9.21% of the 22,503,907 common shares outstanding as of October 31, 2017, according to the Form 10-Q filed by the Issuer with the SEC on November 6, 2017. None of the individual Funds beneficially own a number of shares of Common Stock representing more than 5% of the outstanding shares of Common Stock.

(b)    MAC, MDRA GP and Monarch GP share voting and dispositive power over 2,073,400 shares of Common Stock held directly by the Funds with each applicable Fund directly holding such shares.

(c)    Schedule II hereto sets forth all transactions with respect to the Common Stock effected by the Reporting Persons in the past 60 days. All such transactions were effected in the open market, and per share prices include any commissions paid in connection with such transactions.

(d)    Not applicable.

(e)    Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

The Reporting Persons have entered into an agreement (the “Joint Filing Agreement”) with respect to the joint filing of this statement and any amendment hereto, pursuant to Rule 13d-1(k)(1) promulgated under the Exchange Act. The description of the Joint Filing Agreement contained in this Schedule 13D is qualified in its entirety by reference to the full text of the Joint Filing Agreement, a copy of which is filed as Exhibit 99.2 hereto and which is incorporated herein by reference.

Except as disclosed in this Schedule 13D, there are no contracts, arrangements, understandings or relationships with respect to securities of the Issuer.

Item 7. Material to be Filed as Exhibits

99.1 Letter to the Chief Executive Officer and Board of Directors of the Issuer, dated January 24, 2018

99.2 Joint Filing Agreement, dated as of January 26, 2018, by and among the Reporting Persons

[Signatures on following page]

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: January 26, 2018	MONARCH ALTERNATIVE CAPITAL LP
		By: MDRA GP LP, its General Partner
		By: Monarch GP LLC, its General Partner
	By:	/s/ Michael A. Weinstock
	Name:	Michael A. Weinstock
	Title:	Chief Executive Officer
Dated: January 26, 2018	MDRA GP LP
		By: Monarch GP LLC, its General Partner
	By:	/s/ Michael A. Weinstock
	Name:	Michael A. Weinstock
	Title:	Member
Dated: January 26, 2018	MONARCH GP LLC
	By:	/s/ Michael A. Weinstock
	Name:	Michael A. Weinstock
	Title:	Member

SCHEDULE I

Monarch GP LLC

Name and Position of Officer or Director	Principal Business Address	Principal Occupation or Employment	Citizenship
Andrew Herenstein	535 Madison Avenue New York, NY 10022	Managing Principal of Monarch Alternative Capital LP	United States
Christopher Santana	535 Madison Avenue New York, NY 10022	Managing Principal of Monarch Alternative Capital LP	United States
Michael Weinstock	535 Madison Avenue New York, NY 10022	Chief Executive Officer of Monarch Alternative Capital LP	United States

SCHEDULE II

Reporting Person	Trade Date	Shares Purchased (Sold)		Price
Monarch Alternative Capital LP	11/27/2017		39,038	$	27.61
Monarch Alternative Capital LP	1/19/2018		13,400	$	33.49
Monarch Alternative Capital LP	1/23/2018		60,000	$	36.00

EX-99.1

Exhibit 99.1

LETTER TO THE BOARD OF DIRECTORS

Richard Betz

Chief Executive Officer and Director

Members of the Board of Directors

Resolute Energy Corporation (“Resolute” or the “Company”)

1700 Lincoln Street, Suite 2800

Denver, CO 80203

Dear Rick and Members of the Board of Directors (the “Board”):

Monarch Alternative Capital LP (“Monarch,” “we,” or “our”), an SEC-registered investment advisor, is the beneficial owner of 2,073,400 shares of the Company, representing approximately 9.21% of the shares outstanding. As of the date of writing, we believe, based on publicly available information, that we are the largest beneficial owner of shares of common stock of Resolute.

As you know, we have been long-term passive investors in Resolute. To date, we have supported the Company’s strategy and management, applauding along the way as the team successfully navigated a tumultuous commodity price cycle, unlocked significant value through drilling in the Permian basin, and transformed the Company through a series of divestitures and acquisitions into a more focused growth enterprise with what we believe is some of the world’s most attractive drilling inventory across approximately 21,000 net acres in the heart of the Delaware Basin.

For too long following this transformation, however, Resolute’s share price performance has significantly lagged that of its peers, and its valuation today languishes at a glaring discount to other Permian operators. We highlight these painful realities below in Exhibits 1 and 2. Trading at just 5.5x total enterprise value to 2018 consensus EBITDA, Resolute lags peers by 3.5x on average, a gap which, if closed, would yield a value of over $70 per Resolute share.

Exhibit 1.

Exhibit 2.

	Ticker		1/23/18 Closing Price		Market Cap. ($ mm)		Total Enterprise Value ($ mm)		3Q17 Prod. (KBOED)		TEV / BOEPD		Permian Net Acres		EBITDA (1)						TEV/ EBITDA
															2017E		2018E		2019E		2017E		2018E		2019E
Pioneer Natural Resources Co		PXD	$	186.04		31,658		32,402		276	$	117,520		690,000		2,191		2,965		3,648		14.8x		10.9x		8.9x
Concho Resources Inc		CXO	$	160.53		23,870		26,676		193	$	138,102		610,000		1,777		2,154		2,627		15.0x		12.4x		10.2x
Diamondback Energy Inc		FANG	$	132.31		12,989		14,902		85	$	175,262		191,000		906		1,354		1,842		16.5x		11.0x		8.1x
Cimarex Energy Co		XEC	$	125.05		11,912		12,976		191	$	68,109		216,000		1,180		1,494		1,836		11.0x		8.7x		7.1x
Parsley Energy Inc		PE	$	29.26		9,199		10,452		72	$	146,109		229,000		670		1,174		1,705		15.6x		8.9x		6.1x
RSP Permian Inc		RSPP	$	41.97		6,656		8,088		59	$	137,250		92,300		580		885		1,216		14.0x		9.1x		6.7x
WPX Energy Inc (3)		WPX	$	15.51		6,175		9,264		77	$	119,954		135,000		675		1,191		1,585		13.7x		7.8x		5.8x
Centennial Resource Development		CDEV	$	21.73		5,995		6,363		35	$	183,373		87,917		277		606		898		23.0x		10.5x		7.1x
Energen Corp		EGN	$	58.20		5,657		6,423		81	$	79,000		147,428		613		952		1,160		10.5x		6.7x		5.5x
Matador Resources Co		MTDR	$	33.30		3,611		4,252		42	$	101,343		115,700		316		421		511		13.5x		10.1x		8.3x
Jagged Peak Energy Inc		JAG	$	14.40		3,066		3,097		19	$	161,486		75,200		201		436		626		15.4x		7.1x		4.9x
Callon Petroleum Co		CPE	$	12.54		2,531		3,137		23	$	139,178		60,000		247		408		588		12.7x		7.7x		5.3x
Resolute Energy Corp (3)		REN	$	35.75		805		1,449		23	$	64,025		21,100		152		263		405		9.6x		5.5x		3.6x
Median						6,175		8,088		72	$	137,250		135,000		613		952		1,216		14.0x		8.9x		6.7x
Average						9,548		10,729		90	$	125,439		205,434		753		1,100		1,435		14.2x		9.0x		6.7x
Maximum						31,658		32,402		276	$	183,373		690,000		2,191		2,965		3,648		23.0x		12.4x		10.2x
Minimum						805		1,449		19	$	64,025		21,100		152		263		405		9.6x		5.5x		3.6x

Source: Bloomberg and company filings

(1) Bloomberg consensus estimates.

(2) Production, hedge value and non-Permian asset value backed out of TEV to isolate Permian acreage value. Denominator consists only of Permian acreage.

(3) Production adjusted for asset divestitures.

Resolute’s acreage quality is almost certainly not the culprit for this disparity. Indeed, we and many reputable third party analysts and experts believe Resolute possesses some of the most prolific acreage in the basin, with breakeven oil prices at or below approximately $30/bbl, arguably among the best in the Lower 48.¹ Management itself has said “we think it’s some of the best [acreage] in the basin.”² Similarly, lack of confidence in the Company’s ability to execute seems an equally implausible explanation, as consensus production and capital spending estimates for 2018 are in-line with the midpoint of Resolute’s most recent guidance range.³

Instead, other elements appear to be at play. We believe two in particular weigh heavily on valuation: Resolute’s relative lack of operating scale and comparatively small market capitalization, both of which are apparent from Exhibit 2. Management appears to appreciate the importance of these factors, remarking as recently as August 2017 that “the transition to being a pure-play Delaware [operator] was never meant to suggest that we’re going to sort of sit tight with 21,000 acres and drill within our little patch of the basin… we’ll look for accretive [acquisition] opportunities.”⁴ But we note an important circularity: achieving the former as an independent entity almost certainly depends on growing the latter. Hence, we believe Resolute is left with essentially three options: (1) wait and hope that the Company’s valuation improves, (2) raise capital, including potentially issuing stock at today’s highly dilutive levels, to acquire scale, or (3) explore a sale to, or combination with, another company.

Option 1, we think, is not a true strategy or viable path toward closing the value gap. With current consensus expectations calibrated to the Company’s guidance, an effective remedy will evidently require more than managerial prowess. Option 2 is fraught with obvious complications, and it risks exacerbating the problem at hand. Price tags for comparable acreage in the public and private markets in many cases exceed the implied value per acre at which Resolute trades. Moreover, Resolute’s small size and dramatic undervaluation disadvantages the Company in pursuing a dwindling supply of top-tier Delaware acreage acquisitions. Management itself has openly acknowledged these inherent challenges, noting on its 2Q2017 earnings conference call that “it’s certainly quieted down a little bit on the A&D front… [and] more meaningful opportunities… get more expensive, more challenging, [and a] little bit more competitive.” Option 3, we think, is the surest and quickest path toward addressing the undervaluation of the Company’s shares. We are concerned, however, that a misalignment of interests between stockholders and incumbent management could emerge as merger or sale options present themselves.

535 Madison Avenue New York, NY 10022 T. 212.554.1700 F. 212.554.1701 www.monarchlp.com - 2 -

The direction Resolute takes at this crossroads will no doubt have profound implications for stockholders. We see a clear, compelling path forward. To that end, we outline a series of steps to maximize value for all stockholders and immediately drive toward a successful denouement of the Resolute story:

• Increase stockholder representation on the Board through the immediate appointment of two Monarch-designated directors. We believe this is the most effective and credible way to ensure that the interests of stockholders are voiced and heard in the boardroom, and maintained as the first and foremost consideration when evaluating strategic alternatives;

• Form a committee of the Board consisting of the two Monarch-designees and one other independent director to explore strategic transactions, including a potential sale of the Company or combination with another company in order to maximize value; and

• Engage a reputable financial advisor with deep industry expertise and relationships to assist the newly formed committee and Board in evaluating and executing on potential transactions.

Of course, if subsequent developments, facts or market conditions warrant a different course of action to appropriately address the valuation problems outlined above, we would be open to considering other approaches.

For a multitude of reasons, we believe Monarch is ideally situated to represent the interests of stockholders as the Board undertakes these steps. To name a few:

• As the Company’s largest stockholder, our single greatest motivation is to maximize the value of Resolute’s common stock;

• Our investment in Resolute securities dates back to November 2014 as substantial unsecured bondholders. As a result, we have deep familiarity with the Company and its history, asset base, operations, and senior leadership team;

• We have a long-term institutional track record of adding value through directorships and constructive active involvement in many of the businesses in which we invest, including within the oil and gas sector;

• Joseph Citarrella, a Managing Principal with Monarch and a proposed nominee to the Board, would bring extensive relevant sector and financial expertise in this role. In addition to his investment responsibilities at Monarch, Mr. Citarrella has served since August 2017 as non-executive Chairman of the Board of Vanguard Natural Resources, Inc. (“Vanguard”), a Houston-based independent oil and gas company with operations across Wyoming, Colorado, Texas, Louisiana, and Oklahoma. Mr. Citarrella also serves as a member of Vanguard’s Strategic Opportunities Committee, which is responsible for overseeing an ongoing strategic review of Vanguard’s asset base and development plans. In this capacity, Mr. Citarrella has worked closely with management, the Board, and financial advisor Jefferies LLC to evaluate potential strategic transactions and pursue targeted objectives to maximize stockholder value. Prior to joining Monarch in May 2012, Mr. Citarrella was an Associate at Goldman Sachs in the Global Investment Research group, covering the integrated oil, exploration and production, and refining sectors. Mr. Citarrella received a B.A. in Economics from Yale University.

535 Madison Avenue New York, NY 10022 T. 212.554.1700 F. 212.554.1701 www.monarchlp.com - 3 -

• Patrick Bartels, a Managing Principal with Monarch and our second proposed nominee to the Board, has served on numerous public and private boards and has over 20 years of investment experience, including across complex situations in North America and Europe. Mr. Bartels currently serves as a Director of Arch Coal, Inc. and LifeCare Health Partners. Previously, Mr. Bartels served on the board of directors of WCI Communities Inc. and JL French Automotive Castings, Inc. As a fiduciary for stockholders, Mr. Bartels has a demonstrated record of value-added returns through capital markets transactions and M&A processes. Mr. Bartels holds the Chartered Financial Analyst designation and a bachelor’s degree in accounting, with a concentration in finance, from Bucknell University.

We feel strongly about the Company implementing the recommendations outlined above and are prepared to take whatever steps may be necessary to accomplish this goal. We would prefer to do so cooperatively, as we believe that would be in the best interests of Resolute. To that end, we note that your bylaws provide that a stockholder must submit to the Company any Board nominee not later than 90 days prior to the anniversary of Resolute’s 2017 annual meeting, a deadline which will be upon us quickly. We urge you to act on our suggestions with that in mind. To that end, we would welcome the opportunity to meet with you and members of your Board to discuss these matters.

We further note that, effective as of the delivery of this letter, we have ceased to be passive holders of Resolute stock, and as a result, we will be filing a Schedule 13D with the Securities and Exchange Commission in a matter of days. This filing may well generate inquiry both to the Company and us. We therefore implore you to respond to us as soon as possible.

Sincerely,

/s/ Michael A. Weinstock

Michael A. Weinstock

Chief Executive Officer

Monarch Alternative Capital LP

/s/ Joseph Citarrella

Joseph Citarrella

Managing Principal

Monarch Alternative Capital LP

535 Madison Avenue New York, NY 10022 T. 212.554.1700 F. 212.554.1701 www.monarchlp.com - 4 -

1. Sources: RS Energy’s “Permian Basin Activity Map” and presentation entitled “Permian Basin: The Spectrum of Change” (November 2017); Goldman Sachs initiation report (July 17, 2017); Imperial Capital initiation report (July 18, 2017).

2. Source: IPAA Oil & Gas Investment Symposium transcript (April 4, 2017).

3. Source: Bloomberg consensus estimates and Resolute’s December 5, 2017 investor presentation.

4. Source: Resolute’s 2Q2017 earnings conference call (August 8, 2017).

535 Madison Avenue New York, NY 10022 T. 212.554.1700 F. 212.554.1701 www.monarchlp.com - 5 -

EX-99.2

Exhibit 99.2

JOINT FILING AGREEMENT

PURSUANT TO RULE 13d-1(k)(1)

THIS JOINT FILING AGREEMENT is entered into as of January 26, 2018, by and among the parties hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the common shares, par value $0.0001 of Resolute Energy Corporation and any amendment thereafter signed by each of the undersigned shall be (unless otherwise determined by the undersigned) filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: January 26, 2018	MONARCH ALTERNATIVE CAPITAL LP
		By: MDRA GP LP, its General Partner
		By: Monarch GP LLC, its General Partner
	By:	/s/ Michael A. Weinstock
	Name:	Michael A. Weinstock
	Title:	Chief Executive Officer
Dated: January 26, 2018	MDRA GP LP
		By: Monarch GP LLC, its General Partner
	By:	/s/ Michael A. Weinstock
	Name:	Michael A. Weinstock
	Title:	Member
Dated: January 26, 2018	MONARCH GP LLC
	By:	/s/ Michael A. Weinstock
	Name:	Michael A. Weinstock
	Title:	Member